Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niteesh Bharara

Interventional Pain Medicine Reston, VA Medical Doctor

NPI 1144480989 CMS profile 709644

11800 Sunrise Valley Dr Ste 600, Reston, VA 20191

Open in the dashboard

General payments

$25,152

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Niteesh Bharara of Reston, VA is reported in the CMS Open Payments database as having received $25,152 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,112 57
2024 General $554 14
2023 General $1,443 43
2022 General $1,275 43
2021 General $1,246 45
2020 General $2,377 27
2019 General $15,146 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niteesh Bharara
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Niteesh Bharara were reported at $3,112. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Niteesh Bharara Interventional Pain Medicine median Middle half National median
2019 $15,146 $684 $216–$2,079 $163
2020 $2,377 $382 $122–$1,109 $114
2021 $1,246 $552 $167–$1,554 $132
2022 $1,275 $605 $187–$1,924 $149
2023 $1,443 $671 $195–$1,915 $160
2024 $554 $684 $206–$1,837 $164
2025 $3,112 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arteriocyte Medical Systems, Inc. $14,855 3 payments
  2. Medtronic, Inc. $3,057 78 payments
  3. Abbott Laboratories $2,555 50 payments
  4. AbbVie, Inc. $759 30 payments
  5. MML US, Inc. $697 14 payments
  6. Nevro Corp. $666 14 payments
  7. Medtronic USA, Inc. $312 11 payments
  8. Stimwave Technologies Incorporated $296 3 payments
  9. Aesculap Implant Systems, LLC $190 3 payments
  10. Boston Scientific Corporation $166 6 payments
  11. Other $1,598 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,291 2 payments
  2. Food and Beverage $7,913 249 payments
  3. Travel and Lodging $4,398 13 payments
  4. Consulting Fee $1,550 1 payment
Products named General payments · program years 2019–2025
  1. KYPHON EXPRESS II KYPHOPAK TRAY $1,947 25 payments
  2. Proclaim Family of SCS IPGs $1,064 18 payments
  3. ReActiv8 $697 14 payments
  4. QULIPTA $427 16 payments
  5. Proclaim IPG $373 8 payments
  6. Senza Spinal Cord Stimulation System $356 6 payments
  7. INTELLIS ADAPTIVESTIM $313 23 payments
  8. INTELLIS $312 11 payments
  9. PROCLAIM Neuromodulation $285 8 payments
  10. PROCLAIM Structural Heart $256 2 payments
  11. Other $4,178 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

696

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$23,069

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

33.5%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 13 $4,702
Movantik Naloxegol Oxalate Brand 11 $4,199
Pregabalin Generic 60 $2,857
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 60 $1,955
Oxycodone Hcl Generic 97 $1,716
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 62 $1,621
Tramadol Hcl Er Tramadol Hcl Brand 15 $1,209
Morphine Sulfate Er Morphine Sulfate Brand 58 $1,066
Gabapentin Generic 68 $756
Tramadol Hcl Generic 34 $651

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$309,423

Of which drugs: $20,943

Medicare patients

321

Average age 72

Services billed

7,285

189 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 25%
Depression 25%
Osteoporosis 22%
Diabetes 18%
Chronic kidney disease 15%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 103 650 $3,580
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 129 1,532 $1,173
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 59 264 $77
Injection, fentanyl citrate, 0.1 mg J3010 Office 17 36 $26
Injection, midazolam hydrochloride, per 1 mg J2250 Office 18 39 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $47
$47 — —
QULIPTA
  • AbbVie, Inc. $47
$47 — —
BOTOX
  • AbbVie, Inc. $40
$40 — —
UBRELVY
  • AbbVie, Inc. $21
$21 — —
HORIZANT
  • CutisPharma, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record